Twist Bioscience Co. (NASDAQ:TWST) Shares Purchased by Vanguard Group Inc.

Vanguard Group Inc. grew its position in shares of Twist Bioscience Co. (NASDAQ:TWST) by 3.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,807,183 shares of the company’s stock after buying an additional 189,791 shares during the period. Vanguard Group Inc. owned about 9.74% of Twist Bioscience worth $269,860,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. boosted its holdings in Twist Bioscience by 4.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 524,942 shares of the company’s stock worth $23,717,000 after purchasing an additional 24,582 shares during the period. FMR LLC boosted its holdings in shares of Twist Bioscience by 6.0% in the 3rd quarter. FMR LLC now owns 218,561 shares of the company’s stock valued at $9,875,000 after buying an additional 12,327 shares during the period. BNP Paribas Financial Markets grew its position in shares of Twist Bioscience by 128.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 38,032 shares of the company’s stock valued at $1,718,000 after buying an additional 21,357 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Twist Bioscience by 2.3% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,243 shares of the company’s stock worth $734,000 after acquiring an additional 363 shares during the period. Finally, Verition Fund Management LLC lifted its holdings in Twist Bioscience by 315.5% in the third quarter. Verition Fund Management LLC now owns 25,093 shares of the company’s stock worth $1,134,000 after acquiring an additional 19,054 shares during the last quarter.

Analysts Set New Price Targets

TWST has been the topic of a number of research reports. JPMorgan Chase & Co. increased their price target on Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a research report on Tuesday, February 4th. Guggenheim set a $50.00 target price on Twist Bioscience in a research report on Friday, March 28th. Robert W. Baird boosted their price target on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a report on Tuesday, February 4th. Wolfe Research initiated coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective on the stock. Finally, Scotiabank restated an “outperform” rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $54.10.

Twist Bioscience Trading Down 3.5 %

Shares of NASDAQ:TWST opened at $36.19 on Friday. Twist Bioscience Co. has a twelve month low of $27.41 and a twelve month high of $60.90. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. The firm has a market cap of $2.16 billion, a P/E ratio of -10.71 and a beta of 2.34. The company has a 50 day moving average of $43.80 and a 200-day moving average of $45.10.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The firm had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. During the same period in the prior year, the firm posted ($0.75) earnings per share. The firm’s revenue for the quarter was up 24.1% compared to the same quarter last year. As a group, analysts anticipate that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Emily M. Leproust sold 1,726 shares of the stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $41.68, for a total transaction of $71,939.68. Following the completion of the sale, the chief executive officer now directly owns 660,966 shares of the company’s stock, valued at $27,549,062.88. This represents a 0.26 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Robert Chess sold 2,940 shares of Twist Bioscience stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $53.13, for a total transaction of $156,202.20. Following the completion of the transaction, the director now owns 18,173 shares in the company, valued at approximately $965,531.49. This trade represents a 13.93 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 33,682 shares of company stock valued at $1,582,011 over the last three months. Company insiders own 3.01% of the company’s stock.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.